{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:18:16Z","timestamp":1791242296237,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejim.2023.04.021","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T17:25:03Z","timestamp":1683307503000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-7648","authenticated-orcid":false,"given":"Mohammad","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Bussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Filippone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-1373","authenticated-orcid":false,"given":"Andrew J.","family":"Foy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2023.04.021_bib0001","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"17","key":"10.1016\/j.ejim.2023.04.021_bib0002","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.021_bib0003","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.111.173799","article-title":"Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea","volume":"58","author":"Witkowski","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.021_bib0004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/heartjnl-2018-313786","article-title":"Resistant hypertension in times of changing definitions and treatment recommendations","volume":"105","author":"Nazarzadeh","year":"2019","journal-title":"Heart"},{"issue":"21","key":"10.1016\/j.ejim.2023.04.021_bib0005","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","article-title":"Resistant hypertension: a review of diagnosis and management","volume":"311","author":"Vongpatanasin","year":"2014","journal-title":"JAMA"},{"issue":"d5928","key":"10.1016\/j.ejim.2023.04.021_bib0006","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.021_bib0007","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saud J Kidney Dis Transpl"},{"issue":"9","key":"10.1016\/j.ejim.2023.04.021_bib0008","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10","key":"10.1016\/j.ejim.2023.04.021_bib0009","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"issue":"27","key":"10.1016\/j.ejim.2023.04.021_bib0010","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/MD.0000000000000162","article-title":"Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT)","volume":"93","author":"V\u00e1clav\u00edk","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"10008","key":"10.1016\/j.ejim.2023.04.021_bib0011","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.021_bib0012","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"issue":"10293","key":"10.1016\/j.ejim.2023.04.021_bib0013","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejim.2023.04.021_bib0014","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/HYPERTENSIONAHA.115.05283","article-title":"Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension","volume":"65","author":"Desch","year":"2015","journal-title":"Hypertension"},{"issue":"15","key":"10.1016\/j.ejim.2023.04.021_bib0015","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejim.2023.04.021_bib0016","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/HJH.0000000000000977","article-title":"Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial","volume":"34","author":"Mathiassen","year":"2016","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.021_bib0017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0000000000001584","article-title":"Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV","volume":"36","author":"Schmieder","year":"2018","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.021_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","article-title":"Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.ejim.2023.04.021_bib0019","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.ejim.2023.04.021_bib0020","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1524-6175.2007.07244.x","article-title":"Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study","volume":"9","author":"Black","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9699","key":"10.1016\/j.ejim.2023.04.021_bib0021","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.021_bib0022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1016\/j.ejim.2023.04.021_bib0023","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/HJH.0000000000001264","article-title":"Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension","volume":"35","author":"Schneider","year":"2017","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2023.04.021_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13104-020-05067-5","article-title":"The impact of propranolol on nitric oxide and total antioxidant capacity in patients with resistant hypertension-evidence from the APPROPRIATE trial","volume":"13","author":"Ranasinghe","year":"2020","journal-title":"BMC Res Notes"},{"issue":"7","key":"10.1016\/j.ejim.2023.04.021_bib0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"10367","key":"10.1016\/j.ejim.2023.04.021_bib0026","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"9671","key":"10.1016\/j.ejim.2023.04.021_bib0027","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.04.021_bib0028","article-title":"A systematic review, meta-analysis, and meta regression of the sham controlled renal denervation randomized controlled trials","author":"Ahmed","year":"2022","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.021_bib0029","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","article-title":"Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and\/or Cost or Just a Men's Issue?","volume":"21","author":"Manolis","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.021_bib0030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semnephrol.2014.04.004","article-title":"Role of aldosterone blockade in resistant hypertension","volume":"34","author":"Egan","year":"2014","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.ejim.2023.04.021_bib0031","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"issue":"34","key":"10.1016\/j.ejim.2023.04.021_bib0032","doi-asserted-by":"crossref","first-page":"e21694","DOI":"10.1097\/MD.0000000000021694","article-title":"Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.021_bib0033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.HYP.0000111139.94378.74","article-title":"Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension","volume":"43","author":"da Silva","year":"2004","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.021_bib0034","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.lfs.2013.12.209","article-title":"Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development","volume":"118","author":"Donato","year":"2014","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.021_bib0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08037051.2016.1208730","article-title":"Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis","volume":"26","author":"Yuan","year":"2017","journal-title":"Blood Press"},{"key":"10.1016\/j.ejim.2023.04.021_bib0036","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/VHRM.S133921","article-title":"Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?","volume":"14","author":"Correale","year":"2018","journal-title":"Vasc Health Risk Manag"},{"issue":"5411","key":"10.1016\/j.ejim.2023.04.021_bib0037","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bmj.2.5411.725","article-title":"Use of propranolol (inderal) in treatment of hypertension","volume":"2","author":"Prichard","year":"1964","journal-title":"Br Med J"},{"issue":"9496","key":"10.1016\/j.ejim.2023.04.021_bib0038","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(05)67573-3","article-title":"Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis","volume":"366","author":"Lindholm","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejim.2023.04.021_bib0039","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/01.hjh.0000249685.58370.28","article-title":"How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis","volume":"24","author":"Bradley","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.04.021_bib0040","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/642416","article-title":"Pathophysiology of resistant hypertension: the role of sympathetic nervous system","author":"Tsioufis","year":"2011","journal-title":"Int J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2023.04.021_bib0041","doi-asserted-by":"crossref","first-page":"R633","DOI":"10.1152\/ajpregu.00258.2005","article-title":"Physiology in perspective: the Wisdom of the Body. Neural control of the kidney","volume":"289","author":"DiBona","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"10.1016\/j.ejim.2023.04.021_bib0042","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2215\/CJN.08500812","article-title":"Vascular and renal hemodynamic changes after renal denervation","volume":"8","author":"Ott","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ejim.2023.04.021_bib0043","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00392-015-0832-5","article-title":"Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension","volume":"104","author":"P\u00f6ss","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"10.1016\/j.ejim.2023.04.021_bib0044","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/HJH.0000000000001025","article-title":"Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial","volume":"34","author":"Oliveras","year":"2016","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.04.021_bib0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","article-title":"Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study","volume":"67","author":"Rosa","year":"2016","journal-title":"Hypertension"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523001346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:39:14Z","timestamp":1760607554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523001346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":45,"alternative-id":["S0953620523001346"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.04.021","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}